Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved
Why Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% today, November 18, 2026
Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% on November 18, 2026, closing at $398.08 versus $421.99 the prior session (close-to-close, from daily closes). After multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. Source: FMP price data; BestStocks detection.
Madrigal Pharmaceuticals (MDGL) moved -5.41% from $420.86 to $398.08 on 2026-11-18 after multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations.
What to watch next: MDGL earnings scheduled for 2026-02-18 (consensus EPS estimate $1.43) and any updates to the status or scope of the ongoing securities investigations.
Earlier sessions that moved MDGL
- +8.3%An ongoing securities investigation announcement by Kaplan Fox (newsfilecorp.com).
- −8.1%After reporting Q3 2026 earnings. Read the November 3, 2026 analysis →
- −4.2%Driven by Bank of America Securities lowering its price target to $533 from $543 and maintaining a Neutral rating, citing a lack of near-term clinical catalysts in the sector (web_catalyst).
- +4.6%We checked news, earnings reports, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −3.2%Valuation reassessment rather than operational news.
- −3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +5.2%Following major institutional investor disclosures in SEC 13F filings released August 26.
Madrigal Pharmaceuticals, Inc. (MDGL) shares tumbled 5.7% to $398.08 as of November 18, 2026, a significant decline from the prior close of $421.99. BestStocks flagged the session as a major change for MDGL. The move is tied to price move down. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MDGL fell 5.7% to $398.08
Madrigal Pharmaceuticals (MDGL) moved -5.41% from $420.86 to $398.08 on 2026-11-18 after multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. MDGL earnings scheduled for 2026-02-18 (consensus EPS estimate $1.43) and any updates to the status or scope of the ongoing securities investigations.
What it means for Madrigal Pharmaceuticals, Inc. investors
For Madrigal Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Sharp 5.7% decline — elevated risk. Wall Street's consensus price target sits at $669.22, implying +68.1% upside from $398.08. BestStocks rates the overall signal quality medium (65/100). With earnings roughly 92 days out, the next report is the most likely near-term test of the move.
MDGL price reaction
MDGL last traded at $398.08, down $23.91 (-5.67%) from the previous close of $421.99. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $396.32 and $467.54, and it currently sits about 2% of the way up that band.
Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)
The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $669.22, 68.1% above the recent $398.08. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.
The bullish case
- Wall Street's consensus price target of $669.22 implies +68.1% upside from $398.08.
- The Street's most bullish target is $962.00 (+141.7%).
- Positive price momentum.
The bearish case
- Material negative event.
- Sharp 5.7% decline — elevated risk.
- Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MDGL
In-depth MDGL event analyses
Frequently asked questions about MDGL
Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?
Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% on November 18, 2026, closing at $398.08 versus $421.99 the prior session (close-to-close, from daily closes). After multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. Source: FMP price data; BestStocks detection.
How much did MDGL stock fall?
MDGL lost 5.67% ($23.91) versus the prior close of $421.99, last trading at $398.08 on 1.8× average volume.
When is Madrigal Pharmaceuticals, Inc.'s next earnings date?
MDGL's next earnings report is estimated for 2027-02-18 — about 92 days away.
What is the analyst price target for MDGL?
The consensus analyst price target for MDGL is $669.22, about 68.1% above the current $398.08. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.
How BestStocks tracks MDGL
This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
